Production yields of<sup>Nat</sup>Zn(p,x)<sup>67</sup>Ga reaction in the energy range of 1.6 to 2.5 MeV

Wächter, J. De; Miranda, P.; Cancino, Simón; Morales, J. R.; Dinator, M. I.

doi:10.1088/1742-6596/134/1/012040

Cited by 1 publication

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50 In addition, many ongoing clinical trials are aimed at assessing the therapeutic effi cacy of 90 Y-or 131 I-labeled antibodies in the treatment of non-Hodgkin lymphoma, glioblastoma, colorectal, prostate, and renal cancers, among others. 67 At present, 32 P, 153 Sm, 177 Lu, and 188 Re radionuclides (among others) are being used for β-therapy in ongoing clinical trials. Researchers at the Weill Medical College of Cornell University in New York City are conducting a phase II trial studying the therapeutic effi cacy of [ 177 Lu]-labeled J591, an anti-PSMA antibody, in patients with prostate cancer (Clinical Trial #NCT00859781).…”

Section: Radionuclides For Therapymentioning

confidence: 99%

Unconventional Nuclides for Radiopharmaceuticals

2010

View full text Add to dashboard Cite

Rapid and widespread growth in the use of nuclear medicine for both diagnosis and therapy of disease has been the driving force behind burgeoning research interests in the design of novel radiopharmaceuticals. Until recently, the majority of clinical and basic science research has focused on the development of 11C-, 13N-, 15O-, and 18F-radiopharmaceuticals for use with positron emission tomography (PET) and 99mTc-labeled agents for use with single-photon emission computed tomography (SPECT). With the increased availability of small, low-energy cyclotrons and improvements in both cyclotron targetry and purification chemistries, the use of “nonstandard” radionuclides is becoming more prevalent. This brief review describes the physical characteristics of 60 radionuclides, including β+, β−, γ-ray, and α-particle emitters, which have the potential for use in the design and synthesis of the next generation of diagnostic and/or radiotherapeutic drugs. As the decay processes of many of the radionuclides described herein involve emission of high-energy γ-rays, relevant shielding and radiation safety issues are also considered. In particular, the properties and safety considerations associated with the increasingly prevalent PET nuclides 64Cu, 68Ga, 86Y, 89Zr, and 124I are discussed.

show abstract

Section: Radionuclides For Therapymentioning

confidence: 99%